Wild-type LRP6 inhibits, whereas atherosclerosis-linked LRP6R611C increases PDGF-dependent vascular smooth muscle cell proliferation.
about
Low-density lipoprotein receptor (LDLR) family orchestrates cholesterol homeostasisMAPK phosphorylation of connexin 43 promotes binding of cyclin E and smooth muscle cell proliferation.ICAM-1-Targeted Liposomes Loaded with Liver X Receptor Agonists Suppress PDGF-Induced Proliferation of Vascular Smooth Muscle Cells.Mutation in KERA identified by linkage analysis and targeted resequencing in a pedigree with premature atherosclerosis.The LRP6 rs2302685 polymorphism is associated with increased risk of myocardial infarction.Paeonol Inhibits Proliferation of Vascular Smooth Muscle Cells Stimulated by High Glucose via Ras-Raf-ERK1/2 Signaling Pathway in Coculture Model.PDGF: the nuts and bolts of signalling toolbox.Ezetimibe suppresses cholesterol accumulation in lipid-loaded vascular smooth muscle cells in vitro via MAPK signalingTargeting the PDGF signaling pathway in the treatment of non-malignant diseases.Modulation of canonical Wnt signaling by the extracellular matrix component biglycan.LRP5 deficiency down-regulates Wnt signalling and promotes aortic lipid infiltration in hypercholesterolaemic mice.Sclerostin inhibits osteoblast differentiation without affecting BMP2/SMAD1/5 or Wnt3a/β-catenin signaling but through activation of platelet-derived growth factor receptor signaling in vitroAdiponectin inhibits Wnt co-receptor, Lrp6, phosphorylation and β-catenin signaling.LRP-6 is a coreceptor for multiple fibrogenic signaling pathways in pericytes and myofibroblasts that are inhibited by DKK-1.LRP6 enhances glucose metabolism by promoting TCF7L2-dependent insulin receptor expression and IGF receptor stabilization in humans.A rare variant in MCF2L identified using exclusion linkage in a pedigree with premature atherosclerosisIncreased levels of low-density lipoprotein cholesterol within the normal range as a risk factor for nonalcoholic fatty liver disease.Rare nonconservative LRP6 mutations are associated with metabolic syndrome.Ephrin-B2 controls PDGFRβ internalization and signaling.Functional analysis LRP6 novel mutations in patients with coronary artery disease.Molecular biology of atherosclerosis.Regulation of signaling interactions and receptor endocytosis in growing blood vessels.Low-Density Lipoprotein Receptor-Related Protein 6 (LRP6) Is a Novel Nutritional Therapeutic Target for Hyperlipidemia, Non-Alcoholic Fatty Liver Disease, and Atherosclerosis.Harnessing low-density lipoprotein receptor protein 6 (LRP6) genetic variation and Wnt signaling for innovative diagnostics in complex diseases.Nilotinib attenuates endothelial dysfunction and liver damage in high-cholesterol-fed rabbits.Neurorestorative Responses to Delayed Human Mesenchymal Stromal Cells Treatment of Stroke in Type 2 Diabetic Rats.Wnt signaling, a novel pathway regulating blood pressure? State of the art review.Wnt signaling in cardiovascular disease: opportunities and challenges.Biological characteristics of foam cell formation in smooth muscle cells derived from bone marrow stem cells.Xeroderma Pigmentosum Group D (XPD) Inhibits the Proliferation Cycle of Vascular Smooth Muscle Cell (VSMC) by Activating Glycogen Synthase Kinase 3β (GSK3β)
P2860
Q24608930-7670BC20-6D63-4ADE-88C9-AF6C17BF1AA8Q30418359-EA445FC8-DE08-4779-9B65-8AB591A3E06EQ33633564-FFC8DD8B-A599-416A-9A29-E2D759B453E0Q33690049-AD3F20BC-74FB-4681-AB7A-6CD23DC1192FQ33761093-3B138C25-5034-49CB-A391-629A1A926F58Q33796768-689668CF-6C2D-4B2B-9C0A-3FC152C960DDQ33965086-AF645883-2FDB-4A41-BBE4-81F3ADA72E8DQ34138315-719D4EC3-DEE3-45F0-8F0C-60934B5C0574Q34352802-A791455A-4058-43E3-AE24-39042A395131Q35345488-07715C03-74E5-47D8-91AE-1422EA5DC858Q35390964-74532F2C-4941-436C-B440-26749C2C792CQ36256294-4BA93359-07ED-4F72-B45C-18FA5D3966B0Q36563098-A7259124-5C6D-4558-B93F-91A7C9E15EBBQ36567999-5345D912-C30F-4CCF-A8CF-76EAEE30953AQ36660096-0848D28D-F3C6-4EB7-9F55-8ED7FB1B5494Q36695830-4772D7AE-AC05-406D-B7AE-09F2AF9529B0Q36905761-D4723805-D62D-4302-A744-C3BE108BF8A4Q37100153-0E52B892-55B8-4244-8F53-B80A22AD128AQ37388899-D9B7A935-E941-4F9D-AB39-A143317EF42BQ37464581-F4C2035E-82EF-4EF4-9646-46A3A4346CE1Q38125279-8BB0AFF3-D1CA-479B-89AF-34C586F99EBCQ38284407-CD76C48B-074B-4240-88C1-A419A4727695Q38517043-3B947F35-DA73-41BD-A4A3-154056D15903Q38659378-167A8092-F49C-4A51-A2FC-0E13B380665EQ39110979-60FDD70C-1C29-4DF0-BAD1-B7E91C0EAF0AQ39301427-C264F507-0141-479E-98C8-3BF5A03F3D9BQ39316445-7E1133C2-6FE2-49A3-8281-E0A1D77AF60CQ39445406-8BE39C56-2E0A-4624-8A9E-13D27F4D32C8Q41995847-59B2CD5A-839C-4035-AC25-88EDDCF86729Q58700623-4AF26CAB-A226-4AD5-9B9C-FBD8428097B5
P2860
Wild-type LRP6 inhibits, whereas atherosclerosis-linked LRP6R611C increases PDGF-dependent vascular smooth muscle cell proliferation.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Wild-type LRP6 inhibits, where ...... oth muscle cell proliferation.
@ast
Wild-type LRP6 inhibits, where ...... oth muscle cell proliferation.
@en
Wild-type LRP6 inhibits, where ...... oth muscle cell proliferation.
@nl
type
label
Wild-type LRP6 inhibits, where ...... oth muscle cell proliferation.
@ast
Wild-type LRP6 inhibits, where ...... oth muscle cell proliferation.
@en
Wild-type LRP6 inhibits, where ...... oth muscle cell proliferation.
@nl
prefLabel
Wild-type LRP6 inhibits, where ...... oth muscle cell proliferation.
@ast
Wild-type LRP6 inhibits, where ...... oth muscle cell proliferation.
@en
Wild-type LRP6 inhibits, where ...... oth muscle cell proliferation.
@nl
P2093
P2860
P356
P1476
Wild-type LRP6 inhibits, where ...... oth muscle cell proliferation.
@en
P2093
Aiping Lin
Ali R Keramati
George Tellides
Rajvir Singh
Richard P Lifton
Saeed Faramarzi
Shrikant Mane
Zhi-jia Ye
P2860
P304
P356
10.1073/PNAS.1019443108
P407
P577
2011-01-18T00:00:00Z